Business Context and Reporting Period
This Form 8-K was filed by Camp Nine, Inc. on April 30, 2014. The filing reports significant corporate governance changes, including the appointment of new leadership and the resignation of former officers. Additionally, the company announced negotiations for a share exchange agreement with Relmada Therapeutics, Inc., a clinical-stage pharmaceutical company focused on chronic pain treatments.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for Camp Nine, Inc. or Relmada Therapeutics, Inc. The document focuses on corporate events rather than financial performance data.
Material Changes
- Leadership Transition: Elliot Maza was appointed as Director, CEO, CFO, President, Secretary, and Treasurer. Michael Garcia resigned from all his positions. The board stated there was no disagreement regarding operations or policies.
- Proposed Merger: Camp Nine entered into negotiations for a Share Exchange Agreement to acquire 100% of Relmada Therapeutics, Inc. in exchange for 80% of Camp Nine's stock. If completed, Relmada would become a wholly-owned subsidiary.
- Corporate Address: The company's principal executive offices moved to 50 Sylvan Avenue, Suite 101, Englewood Cliffs, NJ 07632.
Guidance, Outlook, and Risks
Outlook and Strategy: Upon successful completion of the transaction, Camp Nine expects to change its name to Relmada Therapeutics, Inc., reincorporate in Delaware, and shift its business plan to focus on Relmada's drug development pipeline. Relmada's strategy involves developing novel drugs for chronic pain with lower development costs and risk profiles than new chemical entities.
Conditions Precedent: The transaction is subject to several conditions, including shareholder approval and the raising of new equity financing. Camp Nine must raise $2 million, and Relmada must raise a minimum of $5 million prior to closing.
Risks and Contingencies: The agreement is currently executory and subject to approval. There is no written employment or compensation agreement in place for the newly appointed CEO, Elliot Maza, at the time of filing.
Investor Verification Checklist
- Verify the status of the Share Exchange Agreement and whether shareholder approval has been obtained.
- Confirm the progress of the required equity financing ($2 million for Camp Nine and $5 million for Relmada).
- Review the final terms of the employment and compensation agreement for Elliot Maza.
- Monitor the regulatory filings regarding the name change and reincorporation in Delaware.